Drug intelligence / Profile preview

THOR-221

Development stage: Preclinical
Lead developer: THOR Biopharma
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

THOR-221 is an antisense oligonucleotide (ASO) therapeutic candidate being developed by THOR Biopharma. Currently in the preclinical stage of development, specifically candidate optimization, THOR-221 is designed to modulate the expression of an undisclosed proprietary target referred to as Target G. As an ASO, its mechanism of action typically involves binding to target mRNA to induce degradation or inhibit translation, thereby reducing the levels of the associated protein.

Targets

Target G (Wave Life Sciences Undisclosed Lung Target)

Beyond the preview

Go deeper on THOR-221.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on THOR-221.

Explore the full profile